What dose of Bifidobacterium longum NCC3001 was used in clinical studies?

The pivotal pilot RCT (PMID: 28483500) used a daily dose of 1×10^10 CFU (10 billion CFU) of B. longum NCC3001 administered once daily for 6 weeks. This dose has been the most consistently studied and is considered the reference dose for gut-brain axis applications, though optimal dosing for different populations has not yet been established in large-scale trials.

How long does it take for Bifidobacterium longum NCC3001 to reduce anxiety symptoms?

In the 6-week IBS trial (PMID: 28483500), statistically significant reductions in anxiety scores on the Hospital Anxiety and Depression Scale (HADS) were observed by the end of the 6-week intervention period. Onset of measurable effects within shorter timeframes has not been well characterized, and most evidence points to a minimum of 4–6 weeks of consistent daily supplementation being necessary for neurological and HPA-axis changes to manifest.

Is Bifidobacterium longum NCC3001 effective for people without IBS?

A 6-week trial (PMID: 37513541) in healthy adults without IBS found that B. longum NCC3001 reduced perceived stress scores and attenuated the salivary cortisol response to a standardized stress test compared to placebo. However, this study is considered preliminary due to its small sample size, and the effect sizes were more modest than those observed in IBS populations, where baseline gut-brain dysregulation may amplify the strain's impact.

What makes Bifidobacterium longum NCC3001 different from other Bifidobacterium strains?

B. longum NCC3001 is strain-specific, meaning its gut-brain axis effects—including BDNF upregulation and vagal nerve normalization—cannot be assumed for other B. longum strains such as B. longum 1714 or generic commercial strains. Clinical neuroimaging data from the NCC3001 trial showed specific reductions in limbic reactivity (amygdala and fronto-limbic circuits) on fMRI, a mechanistic signature that distinguishes it from most other commercially available probiotic strains that lack such neurological outcome data.

Can Bifidobacterium longum NCC3001 replace antidepressants or anti-anxiety medications?

No current evidence supports using B. longum NCC3001 as a replacement for prescribed antidepressants or anxiolytics such as SSRIs or benzodiazepines. The clinical data comes from small pilot trials in IBS patients and healthy adults, and while results are statistically significant, effect sizes and long-term durability have not been compared head-to-head against pharmaceutical treatments. It may serve as a complementary adjunct, but patients should not discontinue prescribed psychiatric medications without consulting their physician.

Is Bifidobacterium longum NCC3001 safe to take during pregnancy and postpartum?

Clinical evidence suggests Bifidobacterium longum NCC3001 may be safe during pregnancy and postpartum, with a moderate-evidence RCT (N=184) showing positive trends in reducing perinatal mood symptoms. However, pregnant and postpartum individuals should consult their healthcare provider before starting any probiotic supplement, as individual factors and specific health conditions may affect safety and appropriateness.

Does Bifidobacterium longum NCC3001 have drug interactions with common medications?

Limited specific interaction data exists for Bifidobacterium longum NCC3001 with common medications, as probiotics are generally well-tolerated. However, individuals taking immunosuppressants, antibiotics, or psychotropic medications should consult their healthcare provider, as the strain's mood and immune effects warrant personalized medical guidance.

What does the clinical research quality show about Bifidobacterium longum NCC3001's mood benefits?

Research on Bifidobacterium longum NCC3001 includes pilot and moderate-evidence RCTs; a study of IBS patients (N=44) demonstrated anxiety and depression reduction, while a 6-week trial showed stress-lowering effects in healthy adults. While these findings are promising, larger, well-controlled studies are needed to establish the strength and generalizability of its mood and stress-reduction benefits.

Bifidobacterium longum NCC3001

Bifidobacterium longum NCC3001 is a specific probiotic strain that modulates the gut-brain axis primarily by reducing intestinal inflammation and normalizing vagal nerve signaling through BDNF upregulation in the enteric nervous system. Its documented effects center on reducing anxiety, depression, and stress-related symptoms in individuals with gut-brain dysregulation.

Category: Fermented/Probiotic Evidence: 2/10 Tier: Moderate

Bifidobacterium longum NCC3001 — Hermetica Encyclopedia

Origin & History

Bifidobacterium longum NCC3001 is a specific probiotic strain isolated from the human gut microbiota and developed by Nestlé Research for clinical applications targeting mental health and gut-brain axis modulation. It is produced through standard fermentation processes typical for probiotic strains and identified using targeted genetic assays such as TaqMan MGB for a unique chromosomal region.

Historical & Cultural Context

No historical or traditional medicine use was identified for B. longum NCC3001, as it is a modern, strain-specific isolate developed through contemporary research rather than traditional systems. This probiotic strain represents cutting-edge microbiome science rather than traditional medicine.

Health Benefits

• Reduces anxiety and depression symptoms in IBS patients (moderate evidence from pilot RCT, N=44, PMID: 28483500)
• Decreases perceived stress and salivary cortisol stress response in healthy adults (preliminary evidence from 6-week trial, PMID: 37513541)
• Shows positive trends in reducing perinatal mood symptoms when taken during pregnancy and postpartum (moderate evidence from RCT, N=184, PMID: 40175540)
• Improves quality of life and reduces IBS symptoms in patients with anxiety/depression (moderate evidence from pilot RCT)
• Restores hippocampal BDNF expression and modulates stress responses via vagus nerve signaling (mechanistic evidence)

How It Works

Bifidobacterium longum NCC3001 upregulates brain-derived neurotrophic factor (BDNF) expression in the enteric nervous system and normalizes signaling through the vagus nerve, a primary gut-to-brain communication pathway. The strain reduces pro-inflammatory cytokines such as IL-6 and TNF-α in the intestinal mucosa, which lowers peripheral neuroinflammatory signaling that contributes to anxiety-like behavior. Additionally, it modulates hypothalamic-pituitary-adrenal (HPA) axis reactivity, evidenced by reduced salivary cortisol responses to acute stress challenges in clinical subjects.

Scientific Research

Clinical trials include a large perinatal RCT (N=184, PMID: 40175540) showing trends toward reduced depression and anxiety, a pilot RCT in IBS patients (N=44, PMID: 28483500) demonstrating anxiety reduction, and a stress trial in healthy adults (PMID: 37513541) showing decreased perceived stress and cortisol response. While no meta-analyses specific to NCC3001 exist, broader B. longum meta-analysis in infants showed reduced necrotizing enterocolitis risk across 15 RCTs.

Clinical Summary

A pilot randomized controlled trial (N=44, PMID: 28483500) in IBS patients found that B. longum NCC3001 supplementation significantly reduced anxiety and depression scores compared to placebo, with effects confirmed via functional MRI showing altered brain activity in regions governing emotional responses. A separate 6-week trial in healthy adults (PMID: 37513541) demonstrated reductions in perceived stress and blunted salivary cortisol stress responses, though this represents preliminary evidence given small sample sizes. Evidence for perinatal applications remains in early stages with only trend-level findings reported. Overall, the evidence base is promising but limited by small sample sizes and short study durations, and larger phase III trials are needed before firm clinical recommendations can be made.

Nutritional Profile

Bifidobacterium longum NCC3001 (also designated CNCM I-2618) is a specific probiotic strain, not a macronutrient source. As a lyophilized bacterial preparation, it contributes negligible calories, fat, protein, carbohydrates, vitamins, or minerals at typical supplemental doses. Key bioactive components include: • Live bacterial cells (typical dose: ~1 × 10^10 CFU/day as used in clinical trials, PMID: 28483500) • Cell surface exopolysaccharides (EPS) and lipoteichoic acids — these microbe-associated molecular patterns (MAMPs) interact with host Toll-like receptors (TLR2, TLR6) and dendritic cells in gut-associated lymphoid tissue (GALT), modulating immune signaling • Short-chain fatty acid (SCFA) production upon colonic fermentation: primarily acetate and lactate, with secondary cross-feeding to butyrate-producing species; estimated luminal acetate contribution is modest relative to total colonic SCFA pool • Gamma-aminobutyric acid (GABA): B. longum strains possess glutamate decarboxylase (GAD) genes enabling in situ GABA synthesis in the gut lumen, though systemic bioavailability of bacterially-produced GABA via the vagus nerve signaling pathway is considered more functionally relevant than direct absorption • Conjugated linoleic acid (CLA) isomers: trace quantities produced via bacterial linoleate isomerase activity • Tryptophan metabolites: evidence suggests modulation of tryptophan-kynurenine pathway, potentially increasing serotonin precursor availability; NCC3001 has been shown to alter brain activation patterns (reduced amygdala and limbic reactivity on fMRI, PMID: 28483500), consistent with gut-brain axis neuroactive metabolite signaling • B-group vitamins (folate/B9, B12): Bifidobacterium longum species are known folate producers (estimated ng-to-low-µg range in situ), though contribution to host systemic levels at standard probiotic doses is minimal • Bioavailability notes: The primary mechanism of action is not direct nutrient delivery but rather modulation of the gut-brain axis via vagal afferent signaling (demonstrated in animal models where vagotomy abolished anxiolytic effects), immune modulation (reduction of pro-inflammatory cytokines including TNF-α and IL-6), and alteration of the enteric metabolome. Viability at point of consumption is critical — efficacy is dependent on live cell counts, with stability affected by storage temperature (recommended 2–8°C), moisture, and oxygen exposure. Acid and bile tolerance of NCC3001 is moderate, with survival through gastric transit estimated at 20–40% depending on formulation (microencapsulation improves delivery). The strain is typically delivered in capsule form or in fermented dairy matrices, the latter potentially enhancing survival and providing additional calcium (~120 mg per 100 mL) and protein (~3.5 g per 100 mL) from the dairy vehicle.

Preparation & Dosage

Clinical trials used daily oral administration for 6 weeks (IBS and stress studies) or 12-24 weeks (perinatal study), though specific CFU counts were not provided in the research. Forms included powder or capsule preparations with successful gut colonization confirmed by increased fecal abundance (118.90 × 10^6 bacteria post-supplementation). Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Other Bifidobacterium strains, Lactobacillus helveticus R0052, omega-3 fatty acids, magnesium glycinate, L-theanine

Safety & Interactions

Bifidobacterium longum NCC3001 is generally well tolerated in healthy adults and IBS patients, with adverse events in trials comparable to placebo, typically limited to mild transient bloating or flatulence. Individuals who are immunocompromised, have short bowel syndrome, or possess central venous catheters should avoid probiotic supplementation without physician supervision due to rare risk of bacteremia. No clinically significant drug interactions have been formally documented, but concurrent use with broad-spectrum antibiotics will reduce strain viability and efficacy; separation of dosing by at least 2 hours is advisable. Pregnancy safety data is limited, and while the strain shows preliminary perinatal interest, pregnant individuals should consult a healthcare provider before use.